Core Viewpoint - Landmark Bancorp, Inc. demonstrated solid profitability growth in Q4 2025, with net earnings increasing to $4.7 million from $3.3 million year-over-year, outperforming the S&P 500 index during the same period [2][3]. Financial Performance - Net interest income rose 19.3% year-over-year to $14.8 million, driven by higher loan yields and lower funding costs [3]. - Diluted earnings per share (EPS) increased to 77 cents in Q4 2025 from 54 cents in Q4 2024, although it was slightly below the 81 cents reported in the previous quarter [2]. - For the full year 2025, net earnings totaled $18.8 million, a 44.4% increase from $13 million in 2024, with diluted EPS rising to $3.07 from $2.15 [3]. Profitability Metrics - Return on average assets improved to 1.17% for both Q4 and 2025, compared to 0.83% in the corresponding periods of 2024 [4]. - Return on average equity increased to 11.88% for Q4 and 12.68% for 2025, up from 9.54% and 10.01% respectively a year earlier [4]. - The net interest margin expanded to 4.03% in Q4 from 3.51% in the year-ago quarter, reflecting higher earning asset yields and lower deposit costs [4]. Balance Sheet Overview - Period-end loans totaled $1.1 billion as of December 31, 2025, slightly lower than the prior quarter but up from $1.05 billion at the end of 2024 [5]. - Total deposits increased by 4.5% year-over-year to $1.4 billion, with growth concentrated in money market and checking accounts [5]. - Non-performing loans decreased to $10 million, or 0.90% of gross loans, down from $13.1 million, or 1.25%, at the end of 2024 [5]. Management Insights - Management characterized the quarter as a strong close to a year of sustained revenue growth and profitability gains, emphasizing pricing discipline on deposits as a key contributor to margin improvement [6]. - The company plans to continue investing in personnel and operational capabilities while maintaining expense control [11]. - Capital levels remain well above regulatory thresholds, with tangible common equity to assets exceeding 8% by the end of 2025 [6]. Earnings Drivers - The primary driver of earnings growth was higher net interest income, supported by rising loan yields and declining funding costs [7]. - Non-interest income declined sequentially due to a loss on the sale of lower-yielding investment securities, part of a strategy to reposition the securities portfolio for improved future returns [7]. Expense Management - Non-interest expenses increased year-over-year due to higher compensation, professional fees, and a valuation allowance on repossessed assets [8]. - Provision for credit losses was $500,000, down from $1.5 million in the year-ago quarter, indicating moderated credit costs [8]. Dividend Declaration - The board declared a quarterly cash dividend of 21 cents per share, payable in February 2026, continuing the company's long-standing record of regular dividend payments [10].

Core Insights - Twist Bioscience Corporation reported first-quarter sales of $103.70 million, a 17% year-over-year increase, surpassing both Wall Street expectations and management guidance [1] - The company aims for profitability through consistent revenue growth, maintaining gross margins above 50%, and disciplined spending to invest in scalable growth opportunities [2] - Fiscal 2026 sales guidance was raised from $425 million-$435 million to $435 million-$440 million, exceeding the consensus estimate of $431.39 million [3] Analyst Ratings - Barclays analyst Luke Sergott maintained an Overweight rating on Twist Bioscience and increased the price target from $39 to $50 [4] - Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating and raised the price target from $42 to $52 [4]

Eli Lilly and Co. (NYSE:LLY) is set to report fourth-quarter earnings on Feb. 4 before the opening bell, with Wall Street forecasting a significant revenue beat driven by its blockbuster weight-loss and diabetes drugs.While topline expectations are high, surging research costs could challenge the company's ability to hit ambitious profit targets.Revenue Expectations Vs. GuidanceAnalysts project fourth-quarter revenue of $17.90 billion, as per Benzinga, a figure that exceeds the implied ceiling of management ...

Core Insights - Twist Bioscience Corporation reported a first-quarter 2026 loss of 50 cents per share, aligning with Wall Street expectations, while sales reached $103.70 million, a 17% year-over-year increase, surpassing both consensus and management guidance [1][4] Financial Performance - The adjusted EBITDA loss for the quarter was $13.4 million, an improvement from a loss of $16.3 million in the previous year [1][2] - Gross margin for the first quarter of fiscal 2026 increased to 52%, up from 48.3% a year ago [2] - The company had approximately $198 million in cash, cash equivalents, and short-term investments as of December 31, 2025 [3] Customer and Product Metrics - Twist shipped products to approximately 2,538 customers in Q1 2026, an increase from about 2,376 customers a year ago [2] - The company shipped approximately 271,000 genes in the quarter, compared to around 205,000 genes in the same period last year [2] Future Outlook - Twist Bioscience raised its fiscal 2026 sales guidance to $435 million-$440 million, compared to the previous range of $425 million-$435 million, with expectations for revenue growth balanced across DSPS and NGS [4] - The company anticipates gross margin to remain above 52% for fiscal 2026 and aims for adjusted EBITDA breakeven in Q4 of fiscal 2026 [4] Analyst Commentary - Analysts express confidence in the long-term revenue growth trajectory of the company, highlighting its aggressive investments in multiple markets that could lead to over 20% growth [6] - The company's strategy to moderate investments while scaling into the FOTF is viewed positively, as it may broaden the appeal of the company's story if executed effectively [6][7]

Core Viewpoint - The Swatch Group reported weaker earnings for 2025 despite a positive sales trend in the second half of the year, with expectations for broad growth in 2026 [1][6]. Financial Performance - The company posted net sales of SFr6.28 billion ($8.11 billion), a decrease of 1.3% at constant exchange rates [1]. - Net profit fell to SFr25 million from SFr219 million the previous year [1]. - Operating profit declined to SFr135 million from SFr304 million, resulting in a margin of 2.1% [2]. - Operating cash flow improved by 52.3% to SFr507 million [3]. Sales and Market Trends - Second-half sales increased by 4.7% at constant currencies, accelerating to 7.2% in the fourth quarter across all price tiers globally [2]. - Revenue, excluding China, Hong Kong SAR, and Macau SAR, grew by 3.4% for 2025 and over 10% in the fourth quarter [4]. - The Americas experienced nearly 20% local-currency growth, primarily driven by the US market [4]. Segment Performance - Within the watches and jewellery segment, operating profit reached SFr549 million, with a margin of 9.5%, down from 10.6% in 2024 [2]. - Retail expansion continued, with over 47% of revenue coming directly from consumers, and online sales surpassing pandemic-era levels in many regions [5]. Future Outlook - Management anticipates substantial growth in 2026 across all price segments, with higher utilization expected to significantly reduce or reverse production losses and enhance profitability [6].

Core Insights - ExxonMobil is the largest International Oil Company by market capitalization and has demonstrated exceptional operational performance, as evidenced by its 2025 financial results [1] Financial Performance - ExxonMobil generated earnings of $28.8 billion and cash flow from operations of $52 billion in 2025, achieving compound annual growth rates of 21% in earnings per share and 10% in cash flow from operations since 2019 [2] - The company reached its highest production volumes in over 40 years, producing 4.7 million barrels of oil equivalent per day, with record outputs in the Permian Basin and offshore Guyana [3] Cost Management - ExxonMobil achieved $3 billion in savings last year, totaling $15.1 billion in savings since 2019, surpassing all other International Oil Companies combined [4] Capital Returns - The company produced $26.1 billion in free cash flow after capital expenditures, supporting $37.2 billion in cash distributions to shareholders, including $17.2 billion in dividends and $20 billion in share repurchases [5] Financial Stability - ExxonMobil ended the year with a net-debt-to-capital ratio of 11% and a cash balance of $10.7 billion, indicating a strong financial position [6] Future Outlook - The company plans to continue its investment strategy and aims to achieve an additional $20 billion in cumulative cost savings by 2030, projecting $25 billion in earnings growth and $35 billion in cash flow growth from 2024 levels by 2030 [7]

Core Viewpoint - Mirum Pharmaceuticals is showing strong performance and growth potential, with shares more than doubling over the past year, but it is not yet consistently profitable [1][2]. Financial Performance - For the first nine months of 2025, Mirum generated $372.4 million in revenue, reflecting a year-over-year increase of 56.8% [3]. - The company reported a loss per share of $0.35 for this period, an improvement from a loss of $1.36 per share in the same period last year [3]. - In Q3 2025, Mirum achieved a net profit of $2.9 million, a significant turnaround from a net loss of $14.2 million in Q3 2024 [4]. Revenue Projections - Mirum expects to achieve $520 million in net product sales for the full 2025 fiscal year, indicating at least a 54.4% growth compared to 2024 [6]. - For 2026, the company is guiding for net sales between $630 million to $650 million, representing a midpoint growth of 23.1% compared to 2025 [6]. Strategic Acquisitions - The company recently acquired Bluejay Therapeutics for $620 million, which may negatively impact short-term profitability due to acquisition costs but is expected to enhance revenue and earnings in the long run [7]. Future Outlook - Mirum has key clinical catalysts that could positively impact its stock price and drive sales growth [8]. - Despite recent strong performance, there are concerns about limited upside potential and the timeline for achieving consistent profitability [8][9].

Core Insights - Verizon Communications reported its strongest subscriber gains in years, leading to a significant increase in stock price by over 11% [1][2]. Subscriber Growth - In the fourth quarter, Verizon achieved its highest quarterly net customer additions since 2019, gaining 616,000 postpaid phone subscribers and 372,000 broadband subscribers [2]. Competitive Strategy - New CEO Dan Schulman aims to strengthen Verizon's market position, stating that the company will no longer be an easy target for competitors like AT&T and T-Mobile [3]. Financial Performance - Verizon's total operating revenue for the fourth quarter rose by 2% year over year to $36.4 billion, while adjusted earnings per share slightly declined by less than 1% to $1.09, surpassing Wall Street's expectations of $1.06 [5]. Future Outlook - The company generated $20.1 billion in free cash flow in 2025, with management projecting a growth of approximately 7% to at least $21.5 billion in 2026, supported by anticipated retail postpaid phone net additions of 750,000 to 1 million [6].

Financial Data and Key Metrics Changes - The company reported adjusted net income of $30 million or $0.06 per diluted share in Q4 2025, compared to a net loss of $0.07 per diluted share in the previous quarter [5][6] - The unadjusted pre-provision, pre-tax net revenue improved by $51 million quarter-over-quarter, while adjusted pre-provision, pre-tax net revenue improved by $45 million versus Q3 [14] - The net interest margin (NIM) expanded by 14 basis points quarter-over-quarter, reaching 2.14%, including a one-time hedge gain of approximately $20 million [17][19] Business Line Data and Key Metrics Changes - The company experienced a 2% growth in net commercial and industrial (C&I) loans on a linked quarter basis, with a total commitment increase of 28% to $3 billion and originations rising by 22% to $2.1 billion [7][10] - The overall commercial real estate (CRE) exposure was reduced by $2.3 billion, with a concentration ratio now below 400% [7][22] - The multifamily portfolio declined by 13% or $4.3 billion year-over-year, with a reserve coverage of 1.83% [22][24] Market Data and Key Metrics Changes - Total CRE balances decreased by $12.1 billion or 25% since year-end 2023, aiding the strategy to diversify the loan portfolio [22] - The company reported a significant reduction in criticized and classified loans, down $330 million quarter-over-quarter, and a decrease in non-accrual loans by $267 million [26] Company Strategy and Development Direction - The company aims to solidify its balance sheet and reposition for growth, focusing on diversifying the loan portfolio and reducing reliance on wholesale funding [9][10] - The strategic initiatives over the past couple of years are expected to drive sustainable growth and profitability going forward [10][30] - The company plans to generate deposit growth across various business lines while maintaining discipline on pricing [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the bank's earning power continuing to strengthen in 2026, driven by growth in net interest income and margin expansion [8][30] - The management team highlighted the importance of proactive management of CRE exposure and improving the bank's credit profile [8][30] - The company anticipates a full year of profitability in 2026, with adjusted EPS forecasted to be in the range of $0.65-$0.70 [16] Other Important Information - The company reduced brokered deposits by almost $8 billion during the year, enhancing its liquidity position [10][19] - The CET1 capital ratio increased by almost 400 basis points, now ranking among the highest capitalized regional banks [9][18] Q&A Session Summary Question: Can you talk about the drivers behind the lowered net interest income guidance? - Management indicated that higher payoff activity, particularly related to multifamily and CRE loans, was the primary driver for the reduction [34][35] Question: How comfortable are you with funding loan growth through core deposit growth? - Management expressed confidence in core deposit growth, leveraging bank branches and new C&I relationships to drive deposits [46][50] Question: What are the prospects for capital return and stock buybacks? - Management noted that the board will consider how to deploy excess capital based on balance sheet growth and non-performing loans [52][53] Question: Can you provide updates on the rent-regulated portfolio and potential impacts from rent freezes? - Management stated that there is ongoing dialogue regarding rent regulations and emphasized that they have not seen a decline in liquidity in the multifamily portfolio [71][76] Question: What is the expected roll-on yield for new C&I and CRE loans? - New C&I loans are coming on at a spread to SOFR of 175 to 300 basis points, while new CRE loans are at 200-225 basis points [89]

Core Viewpoint - Starbucks Corporation is a leading global coffeehouse chain with a focus on premium coffee and customer experience, currently facing a cautious market outlook despite some positive sales growth [1][2]. Financial Performance - In Q1 FY2026, Starbucks reported a 4% growth in global comparable sales and a 5% increase in revenue to $9.92 billion, but experienced a decrease in operating income and a 19% drop in earnings per share year-over-year, indicating challenges in profitability [4][5]. - The stock price is currently at $93.88, with a market capitalization of $106.95 billion, reflecting a 1.35% decrease in price despite a raised price target from $84 to $89 by TD Cowen [2][5]. Store Expansion and Strategy - Starbucks plans to open 650 new stores this year while emphasizing the performance of its existing 16,000 U.S. locations, with a focus on comparable store sales as a key metric for revenue growth [3][5].